AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10352633 — intervention group
Group type: COMPARATOR
Intervention: Licensed facilities
Number of subjects: 301
Study 10352633 — intervention group
Group type: EXPERIMENTAL
Intervention: Unlicensed homes - Physical care
Number of subjects: 301
Study 10352633 — intervention group
Group type: COMPARATOR
Intervention: Licensed facilities - Physical care
Number of subjects: 301
Study 10352633 — intervention group
Group type: EXPERIMENTAL
Intervention: Unlicensed homes - Medical management
Number of subjects: 301
Study 10352633 — intervention group
Group type: COMPARATOR
Intervention: Licensed facilities - Medical management
Number of subjects: 301
Study 7737719 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg oral bromocriptine
Number of subjects: 20
Study 7737719 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2202544 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam (20 mg daily)
Number of subjects: 80
Study 2202544 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac (75‐150 mg daily)
Number of subjects: 80
Study 7021994 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (F)
Number of subjects: 0
Study 7021994 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethacrynic acid (EA)
Number of subjects: 0
Study 7021994 — intervention group
Group type: COMPARATOR
Intervention: Beta-blockade
Number of subjects: 0
Study 7021994 — intervention group
Group type: COMPARATOR
Intervention: Water-bath immersion
Number of subjects: 0
Study 31182150 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted esophagectomy (RE)
Number of subjects: 0
Study 31182150 — intervention group
Group type: COMPARATOR
Intervention: Video-assisted thoracoscopic esophagectomy (VATE)
Number of subjects: 0
Study 28635359 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic paravertebral block (TPVB)
Number of subjects: 90
Study 28635359 — intervention group
Group type: COMPARATOR
Intervention: Intravenous patient-controlled analgesia (IVPCA)
Number of subjects: 90
Study 26009782 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-session brief motivational interview (BMI)
Number of subjects: 60
Study 26009782 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 60
Study 23603204 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV16
Number of subjects: 0
Study 23603204 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV16/18
Number of subjects: 0
Study 23603204 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV16/18/45
Number of subjects: 0
Study 23603204 — intervention group
Group type: COMPARATOR
Intervention: Negative for any of the three combinations
Number of subjects: 0
Study 21093145 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride (0.5 mg/d)
Number of subjects: 4844
Study 21093145 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of dutasteride (0.5 mg/d) and tamsulosin (0.4 mg/d)
Number of subjects: 4844
Study 21093145 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin (0.4 mg/d)
Number of subjects: 4844
Study 19275490 — intervention group
Group type: EXPERIMENTAL
Intervention: ZDV/3TC/LPV/r
Number of subjects: 37
Study 19275490 — intervention group
Group type: EXPERIMENTAL
Intervention: NVP/LPV/r
Number of subjects: 37
Study 19275490 — intervention group
Group type: EXPERIMENTAL
Intervention: ZDV/3TC/LPV/r and NVP/LPV/r
Number of subjects: 37
Study 17252176 — intervention group
Group type: EXPERIMENTAL
Intervention: Early rehabilitation by a rehabilitation specialist, including tailored treatment for post-concussion symptoms (PCS).
Number of subjects: 395
Study 17252176 — intervention group
Group type: COMPARATOR
Intervention: Regular care (Control group).
Number of subjects: 395
Study 15490827 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized tongue inspection method using Bayesian networks
Number of subjects: 525
Study 15490827 — intervention group
Group type: COMPARATOR
Intervention: Traditional tongue diagnosis
Number of subjects: 525
Study 10562778 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (n = 29)
Number of subjects: 51
Study 10562778 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane (n = 22)
Number of subjects: 51
Study 8909010 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (SM) 100 micrograms (four puffs, 25 micrograms per actuation)
Number of subjects: 10
Study 8909010 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (SB) 200 micrograms (four puffs, 50 micrograms per actuation)
Number of subjects: 10
Study 8909010 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P) (four puffs)
Number of subjects: 10
Study 1921253 — intervention group
Group type: EXPERIMENTAL
Intervention: Low salt diet of 20 mmol sodium per day
Number of subjects: 147
Study 1921253 — intervention group
Group type: COMPARATOR
Intervention: High salt diet of 300 mmol sodium per day
Number of subjects: 147
Study 6354604 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg)
Number of subjects: 15
Study 6354604 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide (2.5 mg)
Number of subjects: 15
Study 6354604 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (Atenolol 100 mg + Indapamide 2.5 mg)
Number of subjects: 15
Study 6354604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 31923300 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading of mini-implants with housings and O-rings (insertion torque ≥ 35 Ncm) or soft relining material (insertion torque < 35 Ncm)
Number of subjects: 76
Study 31923300 — intervention group
Group type: COMPARATOR
Intervention: Delayed loading of mini-implants (group B)
Number of subjects: 76
Study 31923300 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups after all housings were picked up
Number of subjects: 76
Study 30934863 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirulina supplementation (SP)
Number of subjects: 501
Study 30934863 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 501
Study 27885399 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral selexipag (400 μg)
Number of subjects: 16
Study 27885399 — intervention group
Group type: COMPARATOR
Intervention: Intravenous selexipag (200 μg)
Number of subjects: 16
Study 26200270 — intervention group
Group type: EXPERIMENTAL
Intervention: Folate receptor-positive circulating tumor cells (CTCs) detection using ligand-targeted PCR technique
Number of subjects: 756
Study 26200270 — intervention group
Group type: COMPARATOR
Intervention: CTCs
Number of subjects: 756
Study 26200270 — intervention group
Group type: COMPARATOR
Intervention: Model combining CTCs with carcinoembryonic antigen, neuron-specific enolase, and Cyfra21-1
Number of subjects: 756
Study 26200270 — intervention group
Group type: EXPERIMENTAL
Intervention: CTC levels
Number of subjects: 756
Study 22657533 — intervention group
Group type: EXPERIMENTAL
Intervention: PZQ syrup
Number of subjects: 1144
Study 22657533 — intervention group
Group type: COMPARATOR
Intervention: Crushed PZQ tablet
Number of subjects: 1144
Study 20531235 — intervention group
Group type: COMPARATOR
Intervention: Positive feedback group
Number of subjects: 0
Study 20531235 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative feedback group
Number of subjects: 0
Study 18822974 — intervention group
Group type: EXPERIMENTAL
Intervention: Needling method for regulating spleen-stomach (acupuncture at Quchi, Hegu, Xuehai, Zusanli, Yinlingquan, Fenglong, Diji, Sanyinjiao)
Number of subjects: 120
Study 18822974 — intervention group
Group type: COMPARATOR
Intervention: Routine therapy for diabetes mellitus with acupuncture at Weiwanxiashu, Feishu, Pishu, Shenshu, Yanglingquan
Number of subjects: 120
Study 15846487 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D WB emission acquisitions of 3 min
Number of subjects: 70
Study 15846487 — intervention group
Group type: COMPARATOR
Intervention: 2D WB emission acquisitions
Number of subjects: 70
Study 11790467 — intervention group
Group type: COMPARATOR
Intervention: Ordinary treatment
Number of subjects: 654
Study 11790467 — intervention group
Group type: COMPARATOR
Intervention: Light multidisciplinary treatment
Number of subjects: 654
Study 11790467 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive multidisciplinary treatment
Number of subjects: 654
Study 11790467 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary treatment
Number of subjects: 654
Study 10606107 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol plus aspirin (C+A)
Number of subjects: 300
Study 10606107 — intervention group
Group type: COMPARATOR
Intervention: Ticlopidine plus aspirin (T+A)
Number of subjects: 300
Study 8941534 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g HMB/day
Number of subjects: 69
Study 8941534 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0 g HMB/day
Number of subjects: 69
Study 8941534 — intervention group
Group type: COMPARATOR
Intervention: HMB supplementation
Number of subjects: 69
Study 1668228 — intervention group
Group type: EXPERIMENTAL
Intervention: Stop-smoking program (n = 19)
Number of subjects: 39
Study 1668228 — intervention group
Group type: COMPARATOR
Intervention: Wait-list condition (n = 20)
Number of subjects: 39
Study 1668228 — intervention group
Group type: EXPERIMENTAL
Intervention: Stop-smoking program
Number of subjects: 39
Study 6406458 — intervention group
Group type: EXPERIMENTAL
Intervention: bupropion, 50 mg
Number of subjects: 12
Study 6406458 — intervention group
Group type: EXPERIMENTAL
Intervention: bupropion, 100 mg
Number of subjects: 12
Study 6406458 — intervention group
Group type: EXPERIMENTAL
Intervention: bupropion, 200 mg
Number of subjects: 12
Study 6406458 — intervention group
Group type: EXPERIMENTAL
Intervention: bupropion, 100 mg with diazepam, 2.5 and 5 mg
Number of subjects: 12
Study 6406458 — intervention group
Group type: EXPERIMENTAL
Intervention: bupropion, 100 mg with alcohol
Number of subjects: 12
Study 6406458 — intervention group
Group type: EXPERIMENTAL
Intervention: d‐amphetamine, 5 and 10 mg
Number of subjects: 12
Study 6406458 — intervention group
Group type: EXPERIMENTAL
Intervention: amitriptyline, 25 mg
Number of subjects: 12
Study 6406458 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 30666017 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold irrigation at 4°C with 17% EDTA and 10 mL of cold saline solution
Number of subjects: 240
Study 30666017 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold irrigation at 2.5°C with 17% EDTA and 10 mL of cold saline solution
Number of subjects: 240
Study 30666017 — intervention group
Group type: EXPERIMENTAL
Intervention: Room temperature irrigation with 17% EDTA and 10 mL of cold saline solution
Number of subjects: 240
Study 29364960 — intervention group
Group type: EXPERIMENTAL
Intervention: Empiric TB treatment (n = 82, 49%)
Number of subjects: 4665
Study 29364960 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest radiography findings compatible with TB (n = 63/82, 77%)
Number of subjects: 4665
Study 29364960 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbiological confirmation of TB
Number of subjects: 4665
Study 29364960 — intervention group
Group type: EXPERIMENTAL
Intervention: Median time to empiric treatment start
Number of subjects: 4665
Study 27477337 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone/Bupropion (NB)
Number of subjects: 2938
Study 27477337 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 2938
Study 24511620 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat bran sausages
Number of subjects: 25
Study 24511620 — intervention group
Group type: EXPERIMENTAL
Intervention: Rye bran sausages
Number of subjects: 25
Study 24511620 — intervention group
Group type: COMPARATOR
Intervention: Wheat flour sausages
Number of subjects: 25
Study 24511620 — intervention group
Group type: COMPARATOR
Intervention: Rye bran bread
Number of subjects: 25
Study 22100188 — intervention group
Group type: EXPERIMENTAL
Intervention: Enriched bread (4% A. nodosum)
Number of subjects: 12
Study 22100188 — intervention group
Group type: COMPARATOR
Intervention: Control bread (0% A. nodosum)
Number of subjects: 12
Study 20070752 — intervention group
Group type: EXPERIMENTAL
Intervention: Test group(1) - 4.3 mm platform
Number of subjects: 31
Study 20070752 — intervention group
Group type: EXPERIMENTAL
Intervention: Test group(2) - 4.8 mm platform
Number of subjects: 31
Study 20070752 — intervention group
Group type: EXPERIMENTAL
Intervention: Test group(3) - 5.5 mm platform
Number of subjects: 31
Study 20070752 — intervention group
Group type: COMPARATOR
Intervention: Control group - 3.8 mm platform
Number of subjects: 31
Study 17959958 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.015 mg/kg midazolam
Number of subjects: 40
Study 17959958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 17599854 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (250 mg in 16 oz of decaffeinated coffee)
Number of subjects: 20
Study 17599854 — intervention group
Group type: COMPARATOR
Intervention: Decaffeinated coffee alone (placebo)
Number of subjects: 20
Study 14722165 — intervention group
Group type: EXPERIMENTAL
Intervention: Words played during surgical stimulation (n=32)
Number of subjects: 64
Study 14722165 — intervention group
Group type: COMPARATOR
Intervention: Words played before surgical stimulation (n=32)
Number of subjects: 64
Study 10866900 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone before induction of anesthesia (Group 1)
Number of subjects: 120
Study 10866900 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone at the end of anesthesia (Group 2)
Number of subjects: 120
Study 10866900 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group 3)
Number of subjects: 120
Study 9408719 — intervention group
Group type: EXPERIMENTAL
Intervention: Small meta-analyses (less than 200 outcome events)
Number of subjects: 0
Study 9408719 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger meta-analyses (several hundred events)
Number of subjects: 0
Study 9408719 — intervention group
Group type: EXPERIMENTAL
Intervention: Well-conducted meta-analyses of large trials using individual patient data
Number of subjects: 0
Study 1591918 — intervention group
Group type: EXPERIMENTAL
Intervention: Trojan-Enz condom
Number of subjects: 49
Study 1591918 — intervention group
Group type: COMPARATOR
Intervention: Tactylon condom
Number of subjects: 49
Study 1591918 — intervention group
Group type: EXPERIMENTAL
Intervention: Both condom brands
Number of subjects: 49
Study 4062332 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthralin minute entire skin treatment (AMEST)
Number of subjects: 43
Study 31126331 — intervention group
Group type: EXPERIMENTAL
Intervention: CMAB009 plus irinotecan
Number of subjects: 0
Study 31126331 — intervention group
Group type: COMPARATOR
Intervention: irinotecan-only
Number of subjects: 0
Study 31126331 — intervention group
Group type: EXPERIMENTAL
Intervention: sequential-CMAB009 therapy
Number of subjects: 0
Study 28990729 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiroxostat 160 mg daily
Number of subjects: 80
Study 28990729 — intervention group
Group type: COMPARATOR
Intervention: Topiroxostat 40 mg daily
Number of subjects: 80
Study 26507720 — intervention group
Group type: EXPERIMENTAL
Intervention: Riociguat (1 mg and 2 mg doses, three times daily for 6 days)
Number of subjects: 36
Study 26507720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 24123617 — intervention group
Group type: EXPERIMENTAL
Intervention: Terminalia chebula 10% mouth rinse
Number of subjects: 78
Study 24123617 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine 0.12% mouth rinse
Number of subjects: 78
Study 24123617 — intervention group
Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 78
Study 22646084 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive Geriatric Assessment (CGA)
Number of subjects: 50
Study 22646084 — intervention group
Group type: COMPARATOR
Intervention: CGA in elderly cancer patients (comparison group)
Number of subjects: 50
Study 21138549 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotherapy with positive mood color
Number of subjects: 156
Study 21138549 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotherapy with high TAS score
Number of subjects: 156
Study 21138549 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotherapy with HAD anxiety
Number of subjects: 156
Study 21138549 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of positive mood color, HAD anxiety, and high TAS score
Number of subjects: 156
Study 17909201 — intervention group
Group type: EXPERIMENTAL
Intervention: Telbivudine (group A)
Number of subjects: 135
Study 17909201 — intervention group
Group type: COMPARATOR
Intervention: Adefovir (group B)
Number of subjects: 135
Study 17909201 — intervention group
Group type: COMPARATOR
Intervention: Adefovir followed by Telbivudine (group C)
Number of subjects: 135
Study 16304151 — intervention group
Group type: EXPERIMENTAL
Intervention: LOP-TPV
Number of subjects: 24
Study 16304151 — intervention group
Group type: EXPERIMENTAL
Intervention: LOP-TPV-RTV
Number of subjects: 24
Study 16304151 — intervention group
Group type: EXPERIMENTAL
Intervention: LOP-RTV
Number of subjects: 24
Study 16304151 — intervention group
Group type: COMPARATOR
Intervention: LOP alone
Number of subjects: 24
Study 11898780 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine therapy for melanoma
Number of subjects: 0
Study 11898780 — intervention group
Group type: EXPERIMENTAL
Intervention: Various vaccine strategies
Number of subjects: 0
Study 11898780 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer immunobiology underlying vaccine therapy
Number of subjects: 0
Study 9862635 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracellular neurofibrillary tangles (eNFTs) stained with antibodies recognizing the 40 carboxy-terminal of Abeta
Number of subjects: 0
Study 9862635 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracellular neurofibrillary tangles (iNFTs) immunoreactive with antibodies to the 42 carboxy-terminal epitope
Number of subjects: 0
Study 9862635 — intervention group
Group type: COMPARATOR
Intervention: Tangle associated amyloid deposits (TAADs)
Number of subjects: 0
Study 7545133 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine (60 mg, twice on the test day)
Number of subjects: 8
Study 7545133 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 2764230 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole (400 mg single dose)
Number of subjects: 150
Study 2764230 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 972199 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.50 mg aerosolized terbutaline sulfate
Number of subjects: 0
Study 972199 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31979057 — intervention group
Group type: EXPERIMENTAL
Intervention: Horticultural therapy (HT)
Number of subjects: 82
Study 31979057 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no specific intervention mentioned)
Number of subjects: 82
Study 30552510 — intervention group
Group type: EXPERIMENTAL
Intervention: BTX‐A injection
Number of subjects: 26
Study 30552510 — intervention group
Group type: COMPARATOR
Intervention: Normal saline injection (Control)
Number of subjects: 26
Study 28084857 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1mg/kg Tramadol
Number of subjects: 60
Study 28084857 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3mg/kg Dexamethasone
Number of subjects: 60
Study 28084857 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 27290958 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine (20 μg/kg intravenous bolus)
Number of subjects: 78
Study 27290958 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (comparable volume intravenous bolus)
Number of subjects: 78
Study 25123526 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume assured non-invasive ventilation (va-NIV)
Number of subjects: 40
Study 25123526 — intervention group
Group type: COMPARATOR
Intervention: Pressure preset non-invasive ventilation (pp-NIV)
Number of subjects: 40
Study 25123526 — intervention group
Group type: EXPERIMENTAL
Intervention: va-NIV
Number of subjects: 40
Study 25123526 — intervention group
Group type: COMPARATOR
Intervention: pp-NIV
Number of subjects: 40
Study 22538219 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical SAR 1118 0.1%
Number of subjects: 13
Study 22538219 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical SAR 1118 1.0%
Number of subjects: 13
Study 22538219 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical SAR 1118 5.0%
Number of subjects: 13
Study 22538219 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical SAR 1118 (all doses)
Number of subjects: 13
Study 19159136 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulated possibility and probability of being stereotyped as unintelligent prior to taking an analytical test
Number of subjects: 0
Study 17463313 — intervention group
Group type: EXPERIMENTAL
Intervention: NeuroThera Laser System (active treatment)
Number of subjects: 120
Study 15866309 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine 600 mg daily
Number of subjects: 523
Study 15866309 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 523
Study 14720008 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (Symbicort) 160/4.5 microg, one inhalation twice daily
Number of subjects: 373
Study 14720008 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (Symbicort)
Number of subjects: 373
Study 14720008 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate
Number of subjects: 373
Study 10554443 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain management flow sheet implementation; protocols derived from AHCPR guidelines; specific details on dosage and duration not available.
Number of subjects: 0
Study 9772596 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuzheng Huoxue Anticancer prescription (FZHXAC)
Number of subjects: 35
Study 2010627 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-adapted influenza B reassortant vaccine
Number of subjects: 75
Study 7046990 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol, 80 mg four times daily
Number of subjects: 18
Study 7046990 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil, 80 mg four times daily
Number of subjects: 18
Study 7046990 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 31891312 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss condition
Number of subjects: 132
Study 31891312 — intervention group
Group type: EXPERIMENTAL
Intervention: Win condition
Number of subjects: 132